Overview

Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease

Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to demonstrate non-inferiority of nitazoxanide compared to vancomycin in resolving symptoms of Clostridium difficile-associated disease (CDAD).
Phase:
Phase 3
Details
Lead Sponsor:
Romark Laboratories L.C.
Treatments:
Nitazoxanide
Vancomycin